NO20083761L - Tumorterapi med et antistoff for vaskulaer endotel vekst faktor og et antistoff for human epitel vekst faktor reseptor type 2 - Google Patents

Tumorterapi med et antistoff for vaskulaer endotel vekst faktor og et antistoff for human epitel vekst faktor reseptor type 2

Info

Publication number
NO20083761L
NO20083761L NO20083761A NO20083761A NO20083761L NO 20083761 L NO20083761 L NO 20083761L NO 20083761 A NO20083761 A NO 20083761A NO 20083761 A NO20083761 A NO 20083761A NO 20083761 L NO20083761 L NO 20083761L
Authority
NO
Norway
Prior art keywords
antibody
growth factor
vascular endothelial
receptor type
tumor therapy
Prior art date
Application number
NO20083761A
Other languages
English (en)
Inventor
Thomas Friess
Werner Scheuer
Max Hasmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37998279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083761(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20083761L publication Critical patent/NO20083761L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en metode for behandling av brystkreft hos pasienter hvor tidligere behandling med et anti-VEGF-antistoff har mislykkes, omfattende administrering til en pasient en terapeutisk effektiv mengde av et anti-HER2-antistoff, mens nevnte anti-VEGF-antistoff-behandling pågår. Oppfinnelsen tilveiebringer også tilsvarende artikler for fremstilling av farmasøytiske preparater.
NO20083761A 2006-03-22 2008-09-01 Tumorterapi med et antistoff for vaskulaer endotel vekst faktor og et antistoff for human epitel vekst faktor reseptor type 2 NO20083761L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06111523 2006-03-22
EP06021815 2006-10-18
PCT/EP2007/002448 WO2007107329A1 (en) 2006-03-22 2007-03-20 Tumor therapy with an antibody for vascular endothelial groeth factor and an antibody for human epithelial growth factor receptor type 2

Publications (1)

Publication Number Publication Date
NO20083761L true NO20083761L (no) 2008-10-09

Family

ID=37998279

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083761A NO20083761L (no) 2006-03-22 2008-09-01 Tumorterapi med et antistoff for vaskulaer endotel vekst faktor og et antistoff for human epitel vekst faktor reseptor type 2

Country Status (25)

Country Link
US (4) US20070224203A1 (no)
EP (2) EP1998805B1 (no)
JP (2) JP5795463B2 (no)
KR (1) KR101089070B1 (no)
AR (1) AR059982A1 (no)
BR (1) BRPI0709025A2 (no)
CA (1) CA2645891A1 (no)
CR (1) CR10244A (no)
DK (2) DK1998805T3 (no)
EC (1) ECSP088753A (no)
ES (2) ES2595238T3 (no)
HK (1) HK1131037A1 (no)
HU (1) HUE029615T2 (no)
IL (1) IL193675A0 (no)
MA (1) MA30290B1 (no)
MX (1) MX2008012014A (no)
MY (1) MY151449A (no)
NO (1) NO20083761L (no)
NZ (1) NZ570921A (no)
PL (2) PL2364732T3 (no)
RU (1) RU2538664C2 (no)
SG (1) SG170730A1 (no)
SI (2) SI2364732T1 (no)
TW (1) TW200812615A (no)
WO (1) WO2007107329A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
KR101135233B1 (ko) * 2000-05-19 2012-04-12 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
CA2526085A1 (en) 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-vegf antibodies
JP2008507520A (ja) 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド Ｈｅｒ２抗体組成物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
TWI441646B (zh) 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
ES2440481T3 (es) 2005-02-23 2014-01-29 Genentech, Inc. Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2012169822A2 (ko) * 2011-06-10 2012-12-13 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
CN104334189A (zh) 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
HRP20211641T1 (hr) 2012-07-13 2022-02-04 Roche Glycart Ag Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
BR112015022210A8 (pt) 2013-03-13 2018-01-23 Genentech Inc formulações de anticorpo
NZ751877A (en) 2013-04-16 2020-04-24 Genentech Inc Pertuzumab variants and evaluation thereof
WO2015164665A1 (en) 2014-04-25 2015-10-29 Genentech, Inc. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
CN107614015A (zh) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) * 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
TW201827077A (zh) 2016-12-28 2018-08-01 美商建南德克公司 晚期her2表現癌症之治療
SI3570884T1 (sl) 2017-01-17 2021-02-26 Genentech, Inc. Subkutane formulacije protiteles HER2
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
HU221343B1 (en) 1992-10-28 2002-09-28 Genentech Inc Use of anti-vegf antibodies for the treatment of cancer
CA2259222A1 (en) 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
EP1106183A3 (en) 1996-10-18 2001-09-12 Genentech, Inc. Antibodies to erbB2 and their therapeutic uses
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE69842174D1 (de) 1997-04-07 2011-04-21 Genentech Inc Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
CN1314917A (zh) 1998-05-15 2001-09-26 伊姆克罗尼系统公司 用辐射和生长因子受体酪氨酸激酶抑制剂治疗人肿瘤
OA11645A (en) 1998-08-27 2004-11-16 Pfizer Prod Inc Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents.
CA2341739C (en) 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
WO2000037502A2 (en) * 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
DE60020812T2 (de) 1999-02-11 2006-05-04 Pfizer Products Inc., Groton Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
IL144559A0 (en) 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
BR0010017A (pt) * 1999-04-28 2002-06-11 Univ Texas Composições e processos para o tratamento de câncer por inibição seletiva de vegf
ES2320311T3 (es) 1999-05-14 2009-05-21 Genentech, Inc. Tratamiento con anticuerpos anti-erbb2.
BR0012195A (pt) 1999-06-25 2002-07-23 Genentech Inc Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2
SI1189641T1 (sl) 1999-06-25 2009-12-31 Genentech Inc Humanizirana protitelesa proti ErbB2 in zdravljenje s protitelesi proti ErbB2
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE60017179T2 (de) * 1999-10-19 2006-01-05 Merck & Co., Inc. Tyrosin kinaseinhibitoren
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
ATE259365T1 (de) 1999-11-30 2004-02-15 Pfizer Prod Inc Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
AU2003222252A1 (en) 2002-03-12 2003-09-29 The General Hospital Corporation Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
DK1501856T3 (da) 2002-04-10 2013-03-25 Genentech Inc Anti-HER2 antistofvarianter
CA2526085A1 (en) 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-vegf antibodies
WO2005000090A2 (en) 2003-05-30 2005-01-06 Medi-Screw, Inc. Medical implant systems
KR20060069825A (ko) 2003-08-01 2006-06-22 제넨테크, 인크. 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
PL1718677T3 (pl) 2003-12-19 2012-09-28 Genentech Inc Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

Also Published As

Publication number Publication date
HUE029615T2 (en) 2017-03-28
BRPI0709025A2 (pt) 2011-06-21
RU2538664C2 (ru) 2015-01-10
NZ570921A (en) 2011-09-30
JP5795463B2 (ja) 2015-10-14
MX2008012014A (es) 2008-10-01
WO2007107329A1 (en) 2007-09-27
EP1998805A1 (en) 2008-12-10
SG170730A1 (en) 2011-05-30
RU2008141433A (ru) 2010-04-27
MA30290B1 (fr) 2009-03-02
AR059982A1 (es) 2008-05-14
TW200812615A (en) 2008-03-16
US20070224203A1 (en) 2007-09-27
HK1131037A1 (en) 2010-01-15
IL193675A0 (en) 2011-08-01
ES2595238T3 (es) 2016-12-28
MY151449A (en) 2014-05-30
SI2364732T1 (sl) 2016-12-30
JP2012207036A (ja) 2012-10-25
US20110064736A1 (en) 2011-03-17
EP1998805B1 (en) 2012-08-22
EP2364732A1 (en) 2011-09-14
JP2009530333A (ja) 2009-08-27
SI1998805T1 (sl) 2012-12-31
KR20080096598A (ko) 2008-10-30
CR10244A (es) 2008-10-29
US20170239353A1 (en) 2017-08-24
PL1998805T3 (pl) 2013-01-31
US9090700B2 (en) 2015-07-28
CA2645891A1 (en) 2007-09-27
ES2392873T3 (es) 2012-12-14
US20150283238A1 (en) 2015-10-08
PL2364732T3 (pl) 2017-01-31
ECSP088753A (es) 2008-10-31
DK2364732T3 (en) 2016-10-10
AU2007229008A1 (en) 2007-09-27
KR101089070B1 (ko) 2011-12-05
DK1998805T3 (da) 2012-10-08
EP2364732B1 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
NO20083761L (no) Tumorterapi med et antistoff for vaskulaer endotel vekst faktor og et antistoff for human epitel vekst faktor reseptor type 2
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
UA117570C2 (uk) Спосіб лікування діабету або діабету, спричиненого ожирінням, або ускладнень при діабеті
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
IN2012DN02826A (no)
AR068532A1 (es) Inhibicion de angiogenesis
HK1120441A1 (en) Drugs for treatment of ovarian cancer
MY183712A (en) Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
UA106756C2 (uk) Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа
NO20071093L (no) Nye anti-IGF-IR-antistoffer og anvendelse derav
TN2011000263A1 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
IN2015KN00350A (no)
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
HRP20161147T1 (hr) Farmaceutski sastav i postupak njegove proizvodnje
MX2023005533A (es) Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.
ATE297751T1 (de) Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MX2021013943A (es) Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application